Attovia targets IPO

Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO

Biopharmaceutical firm Attovia Therapeutics targets a $731.5 million valuation in an upsized US IPO to raise $289 million for developing biologic therapies for immune-mediated diseases. Goldman Sachs